Abstract
B cells play a critical role in the pathogenesis of systemic lupus erythematosus (SLE). We analysed two independent cohorts of healthy donors and SLE patients using a combined approach of flow and mass cytometry. We have found that IgD- CD27+ switched and atypical IgD-CD27- memory B cells, which are increased in SLE, represent heterogeneous populations composed each of three different subsets, such as CXCR5+CD19int, CXCR5-CD19high and CXCR5-CD19low. Here, we characterize a hitherto unknown antigen-experienced CXCR5-CD19low B cell subsets enhanced in SLE and carrying a plasmablast (PB) phenotype enriched for switched immunoglobulins, and expressing CD38, CD95, CD71, PRDM1, XBP-1, and IRF4. CXCR5-CD19low resemble activated B cells with a characteristically diminished B cell receptor responsiveness. CXCR5-CD19low B cells increased with PB frequencies in SLE and upon BNT162b2 vaccination suggesting their interrelationship. Our data suggest that CXCR5-CD19low B cells are precursors of plasmablasts, thus co-targeting this subset may have therapeutic value in SLE.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding This work was supported by DFG grants project Do491/7-5, Do491/10-1, Do491/11-1, TR130 project 24 and LI3540/1-1. The DRFZ, a Leibniz Institute was supported by the Senate of Berlin. ALS is supported by DGRh Research Initiative 2020. ES was supported by a Fellowship of the Berlin Institutes of Health and received a grant from the Federal Ministry of Education and Research (BMBF) (BCOVIT, 01KI20161). HR-A was supported by COLCIENCIAS scholarship No. 727, 2015. Prof. Dörner was granted the HTG EdgeSeq 2020 Autoimmune Panel Research Grant Award for transcriptome analysis using the Immune Response Panel.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was carried out in accordance with the recommendations of the ethics' committee at the Charite University Hospital Berlin with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.